Skip to NavigationSkip to content

Johnson & Johnson

US court upholds ruling that J&J's Remicade patent is invalid

The US Court of Appeals for the Federal Circuit has judged that Johnson & Johnson’s patent for its best-selling arthritis drug Remicade (infliximab) is invalid, upholding a previous decision by the US Patent and Trademark Office (PTO) that the antibodies covered by the patent were already disclosed in an earlier patent.

J&J withdraws controversial vaginal mesh from Australian market

Johnson & Johnson has withdrawn its controversial vaginal mesh product from the Australian market after missing a deadline requiring all such products to carry warnings of potential side-effects. The move follows legal action from more than 700 Australian women who were left in constant pain after having the mesh implanted.

Top Ten most popular articles on this week

The Xmas break is now a distant memory as we move further into January, and with another Friday comes another rundown of the top ten most popular news stories with readers this week.

Among the top stories this week was the news that Shire is to split its business into two distinct units, Nestle could be the frontrunner in the competition to acquire Merck KGaA's consumer health unit, and a remarkable once-weekly, slow-release HIV pill has been developed.

Bayer and J&J successfully reverse $28 million Xarelto court payout

Bayer and Johnson & Johnson have managed to avert a payout of $27.8 million after a Pennsylvania state court judge overturned the award to a couple accusing the pair of firms of failing to adequately warn patients of the internal bleeding risks of its blood thinner drug Xarelto.

J&J’s predicted blockbuster depression posts P2 data

Johnson & Johnson has revealed Phase 2 data for its treatment for depression, esketamine, and the results are positive. The drug is an altered form of ketamine, more commonly known as a party drug, but the chemical is now being widely studied for its therapeutic potential within mental health.

Esketamine is delivered in an intranasal formulation, alongside standard oral antidepressants. J&J has big hopes for the treatment, predicting that it will become a blockbuster treatment should it see approval.'s top ten stories of 2017

After a packed year that has flown by, we've reached the final top ten of 2017. Below you can find the biggest stories of the year that proved most popular with our readers.

It's been a year characterised by uncertainty and scandal, but eventful throughout. From J&J's massive acquisition of Actelion bringing in the year, to Teva's increasingly tragic fall from grace and the shadows cast on the industry and beyond by President Trump and Brexit, 2017 was a standout year for more than just a few reasons.

J&J struck by €25m fine over fentanyl pain patch

Johnson & Johnson has been fined by France’s competition authority, Autorité de la Concurrence, after it alleges the company had intentionally stifled generic competition to its painkiller patch.

The product in question is Durogesic, and the case was brought to the authority by Ratiopharm. The German company, which has since been taken over by Teva (in 2010), suggested that J&J had disparaged generic versions of its product to healthcare professionals.

What will Pfizer do with its second Remicade biosimilar?

Pfizer is now in the unusual position of owning two biosimilars to Johnson & Johnson’s Remicade, though one of these is in partnership with Celltrion.

The FDA approved its second biosimilar, Ixifi, but with it already heavily invested in the commercialisation of Inflectra, alongside Celltrion, the question remains about what Pfizer will choose to do with its second version?

J&J's Darzalex cuts risk of disease progression and death by 50%, new study shows

Johnson and Johnson has revealed data which demonstrates that Darzalex (daratumumab), when combined with a regimen of bortezomib, melphalan and prednisone, was able to reduce the risk of disease progression or death by 50% in newly diagnosed multiple myeloma patients for whom autologous stem cell transplantation is not appropriate.

The findings led senior study author Jesus F San-Miguel to remark that the treatment, developed in partnership with Genmab, “should become a new standard of care in transplant-ineligible multiple myeloma patients.”

J&J opts in on Idorsia’s candidate for $230m

As part of Johnson & Johnson’s acquisition of Actelion, it was able to secure a number of ties with the spinout from the deal, Idorsia. The big pharma company has now decided to take up one of its deals by plumping $230 million on the table to co-develop one of the biotech’s lead candidates.

The therapy is aprocitentan (ACT-132577), which is in development as a treatment for resistant hypertension. Both companies will jointly develop and commercialise the treatment.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches